Digest Network How does it work
Network
/
Society
Io
Not verified

Io Therapeutics, Inc.

What we write about

BiotechnologyMedical Health WellnessWant ads

7 Press releases

View all press releases
23/12/2024
Biotechnology
Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis
Source
Io Therapeutics, Inc.
Issuer
GLOBENEWSWIRE
1.00
0
11/12/2024
Biotechnology
Medical Health Wellness
Want ads
Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody checkpoint inhibitor
Source
Io Therapeutics, Inc.
Issuer
GLOBENEWSWIRE
1.00
0
08/11/2024
Biotechnology
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
Source
Io Therapeutics, Inc.
Issuer
GLOBENEWSWIRE
1.00
0
18/09/2024
Biotechnology
Medical Health Wellness
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
Source
Io Therapeutics, Inc.
Issuer
GLOBENEWSWIRE
1.00
0
16/07/2024
Biotechnology
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)
Source
Io Therapeutics, Inc.
Issuer
GLOBENEWSWIRE
1.00
0
09/07/2024
Biotechnology
Medical Health Wellness
Want ads
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
Source
Io Therapeutics, Inc.
Issuer
GLOBENEWSWIRE
1.00
0
08/07/2024
Biotechnology
Medical Health Wellness
Want ads
Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
Source
Io Therapeutics, Inc.
Issuer
GLOBENEWSWIRE
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0